New can­cer biotech emerges from Stan­ford re­search, with help of No­bel lau­re­ate Car­olyn Bertozzi

A new sol­id tu­mor biotech based on re­search out of Stan­ford Uni­ver­si­ty is tar­get­ing the red-hot fields of can­cer im­munother­a­py and an­ti­body-drug con­ju­gates.

TwoStep Ther­a­peu­tics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER